Showing results (241-250 of 385) with videos related to
Sort By:
Pageof 39
Frontiers in Immunology|November 16, 2020
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple SclerosisTatiana Koudriavtseva, Annunziata Stefanile, Marco Fiorelli, et al.Multiple Sclerosis and Related Disorders|July 27, 2024
Being highly sensitive person negatively impacts on cognitive and psychosocial fatigue in multiple sclerosis patients: A cross-sectional, monocenter studyFabrizia Falco, Federica Lamagna, Antonio Esposito, et al.Multiple Sclerosis and Related Disorders|October 14, 2023
Low serum 25‑hydroxy-vitamin D levels are associated with cognitive impairment in multiple sclerosisAntonio Luca Spiezia, Fabrizia Falco, Andrea Manganelli, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|March 25, 2022
Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy)Marcello Moccia, Giuseppina Affinito, Bruno Ronga, et al.Journal of Clinical Psychology in Medical Settings|January 22, 2022
Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and ResilienceLaura Rosa, Cristiano Scandurra, Alessandro Chiodi, et al.Multiple Sclerosis and Related Disorders|September 28, 2021
ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trialMaria Petracca, Mario Quarantelli, Marcello Moccia, et al.Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 29, 2022
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 PandemicAurora Zanghì, Carlo Avolio, Elisabetta Signoriello, et al.Neurology(R) Neuroimmunology & Neuroinflammation|March 11, 2022
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With OcrelizumabDoriana Landi, Alfonso Grimaldi, Francesca Bovis, et al.Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 29, 2025
Comparative effectiveness, safety and persistence of ocrelizumab versus natalizumab in multiple sclerosis: A real-world, multi-center, propensity score-matched studyElena Barbuti, Alessia Castiello, Valeria Pozzilli, et al.Journal of Neurology|May 10, 2021
Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosisSilvia Tommasin, Sirio Cocozza, Alessandro Taloni, et al.Pageof 39